Coya Therapeutics (NASDAQ:COYA) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Coya Therapeutics (NASDAQ:COYA) from a hold rating to a sell rating in a research report released on Saturday morning.

COYA has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, February 2nd. Finally, D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Coya Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Trading Down 1.4%

Shares of NASDAQ COYA opened at $4.21 on Friday. The stock’s 50-day moving average is $4.69 and its 200 day moving average is $5.52. The stock has a market cap of $98.77 million, a price-to-earnings ratio of -3.31 and a beta of 0.23. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The firm had revenue of $3.96 million during the quarter, compared to analysts’ expectations of $1.93 million. On average, analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in COYA. JPMorgan Chase & Co. purchased a new stake in Coya Therapeutics during the 3rd quarter valued at $28,000. CIBC Private Wealth Group LLC purchased a new position in shares of Coya Therapeutics in the fourth quarter valued at about $47,000. Occudo Quantitative Strategies LP bought a new position in shares of Coya Therapeutics during the fourth quarter valued at about $66,000. Lantern Wealth Advisors LLC purchased a new stake in shares of Coya Therapeutics during the third quarter worth about $66,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Coya Therapeutics during the fourth quarter worth about $81,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.